Alexandre Perrin
Founder and Partner @ Cleverton Ventures
London, United Kingdom
Alexandre Perrin is a Series A investor at Cleverton Ventures in London focused on Artificial Intelligence and Software. Alexandre is currently working on a project in stealth to be announced soon.As the former Head of Ventures at XTX Markets, Alexandre led the venture capital arm of the leading algorithmic market maker that leverages machine learning to trade >18% of daily European equities volumes and >7% of global FX (top 3 globally). He focused on Seed toSeries A companies using ML as a core technology across all verticals (incl. healthcare, self-driving cars, agriculture, architecture…).Iconic initial investments include Anthropic (ranked in the CB Insights 2023 Top 100 most promising AI companies globally), Wayve, BIOS, BlueSkeye AI, SWAPP, Terray Therapeutics (partnered with Calico, an Alphabet company post-investment), IOMED (CB Insights 2023 Digital Health Top 50), and Voiceitt (partnered with Cisco/Webex). He also led follow-on rounds in Traceair and Logically (CB Insights 2023 Top 100 most promising AI companies globally), Turbine (CB Insights 2023 Digital Health Top 50) and oversaw the exit of Dia Imaging to Philips. He served on the boards of over 12 AI/ML startups, including DiA Imaging Analysis (prior to the sale to Philips), TraceAir, Turbine, Logically, Xihelm, and BlueSkeye AI.Before joining XTX Ventures, Alex founded Cleverton Ventures, a venture investment club focusing on early-stage companies in fintech and healthcare.Alexandre is passionate about finding and supporting innovative startups that apply AI/ML to solve real-world problems across various industries and geographies.He also enjoys building communities (such as launching the Young VCs Dinners in 2017, now with >1,000 VC members) and contributing to developing the Deep Tech community. For example, he initiated the Conception X & XTX Ventures partnership. Conception X is the leading deep tech accelerator for PhDs in the UK. He also launched the Creative Destruction Lab "Machine Learning Stream" (pan-European Machine Learning accelerator) by joining forces with HEC Paris and Oxford.His previous roles include overseeing Richard Branson's venture portfolio at Virgin Management (holding company of the Virgin Group and Family Office of the Branson family in a team of two, as an Associate). He supported the execution of the investment process into companies including Upside Foods (fka Memphis Meats), the first lab-grown meat company also backed by Bill Gates and follow-on investments in Slack (productivity tool), Blockchain.com (crypto wallet), Capsule Pharmacy (pharmacy delivery in NYC), DoctorOnDemand (telemedicine), Loansnap (smart mortgage lending); the exit of Ring (connected doorbell) to Amazon. Monitored portfolio of >40 investments, including Transferwise, Slack, and Pinterest.Alexandre is an alumnus of Imperial College and HEC Paris and holds an MSc in Finance and Strategy. He is Swiss-born, speaks four languages and enjoys Kitesurfing and martial arts.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Alexandre Perrin invests in
Stages Alexandre Perrin invests in
Countries Alexandre Perrin invests in
Investment Focus
Industry
- Artificial Intelligence 13 (62%)
- Software 11 (52%)
- Machine Learning 6 (29%)
- Medical 4 (19%)
- Health Care 4 (19%)
Stage
- Series A 8 (38%)
- Venture - Series Unknown 4 (19%)
- Seed 3 (14%)
- Series B 2 (10%)
- Series C 2 (10%)
Country
- United Kingdom 9 (43%)
- United States 7 (33%)
- Israel 2 (10%)
- Spain 1 (5%)
- Hungary 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Terray Therapeutics
|
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $120M / Series B / Oct 17, 2024 | |
IOMED
|
IOMED Medical Solutions develops a medical record management software aimed at structuring clinical data and the generation of artificial intelligence tools.A technology, based on Natural Language Processing, that allows structure clinical text, obtaining reusable data for the development of medical predictive models. It saves costs andeffectively assigns resources by extracting insights from a hospital's clinical notes and data management. The company's software uses artificial intelligence and cognitive computing to organize and visualize medical records information and offers data structuring, integration, and interoperability, providing clinicians with efficiency, information, and savings needed to make more efficient decisions.Alvaro Abella, Gabriel de Maeztu, and Javier Oca founded the company in Barcelona, Catalonia in 2016. | $11M / Series A / Sep 12, 2023 | |
BIOS
|
BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | $20M / Series A / Jun 22, 2023 | |
Anthropic
|
Anthropic conducts AI research and develops AI products, including the Claude AI model family. The company focuses on building AI for human well-being, emphasizing safety in its research, policy work, and product design. Anthropic offers various Claude models, such as Opus and Sonnet, for AI-powered applications and custom experiences, supportingcoding and AI agents. | $450M / Series C / May 23, 2023 | |
Swapp
|
Swapp aims to disrupt the current planning methodologies by providing an Ai-driven end-to-end planning service. The platform enables real estate developers and construction professionals to upload their asset' drawings and programmatic requirements to be analyzed and planned using different sources of data and the power of artificialintelligence. | $11.5M / Series A / May 17, 2023 | |
Tallarium
|
Tallarium uses AI to provide enterprise data solutions and to enable the largest global traders making more informed trading decisions. | $1.9M / Venture - Series Unknown / Mar 13, 2023 | |
Lucida Medical
|
Software to support analysis of MRI for cancer diagnosis, screening and management. Pi(tm), the company's first product, supports diagnosis of prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device. We are interested to speak with investors and hospital partners who share our vision to find cancer early. | $2M / Seed / Mar 01, 2023 | |
Voiceitt
|
Voiceitt is an automatic speech recognition technology platform. Voiceitt provides a new dimension of independence and quality of life for people with speech and motor disabilities, and a useful tool for those who care for and about them. | $4.7M / Venture - Series Unknown / Dec 02, 2022 | |
Turbine
|
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $20.6M / Series A / Nov 22, 2022 | |
Fennel Markets
|
Fennel is a mobile investing app that helps people better understand a company’s impact through digestible ESG data, as well as past and upcoming shareholder votes. With this information, Fennel allows investors to learn more about how companies operate and how they affect the world. Fennel refers to Fennel Markets, Inc., and Fennel FinancialsLLC. Fennel Financials LLC is a wholly owned subsidiary of Fennel Markets, Inc. and is a registered broker-dealer and member of FINRA & SIPC. Securities offered through Fennel Financials LLC, member FINRA. SIPC. | Nov 01, 2022 | |
| See all 21 investments → | |||
Co-Investors
About Cleverton Ventures
Cleverton Ventures is a Venture Capital fund investing in early-stage FinTech. InsurTech. HealthTech. FoodTech
Cleverton Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexandre Perrin
Founder and Partner
|
|||
John Elalouf
Founder and Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexandre Perrin invest in?
Alexandre Perrin invests primarily in Artificial Intelligence, Software and Machine Learning startups, most often at Series A and Venture - Series Unknown stage. Most of the 21 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alexandre Perrin last invest?
The most recent investment recorded for Alexandre Perrin closed in Oct 2024. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
